Podcast 1 Sep 2023Beyond Biotech podcast 61 – Blood Cancer Awareness Month On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed’s CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which […] September 1, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2020 Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the […] November 16, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2018 Cancer Immunotherapy Phase I on Hold After Patient Death The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […] October 10, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2017 What Cancer Therapies did European Biotechs Showcase at ASCO 2017? Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […] June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email